DSDavid P. Speert

David P. Speert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David P. Speert has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients

    by Yvonne C.W. Yau, Felix Ratjen, Elizabeth Tullis, Pearce Wilcox, Andreas Freitag, Mark Chilvers, Hartmut Grasemann, James Zlosnik, David Speert, Mary Corey, et al.


  • Open Access

    Anti-Biofilm and Immunomodulatory Activities of Peptides That Inhibit Biofilms Formed by Pathogens Isolated from Cystic Fibrosis Patients

    by César De la Fuente-Núñez, Sarah C. Mansour, Zhejun Wang, Lucy Jiang, Elena B.M. Breidenstein, Melissa Elliott, Fany Reffuveille, David P. Speert, Shauna L. Reckseidler-Zenteno, Ya Shen, et al.

    Cystic fibrosis (CF) patients often acquire chronic respiratory tract infections due to Pseudomonas aeruginosa and Burkholderia cepacia complex (Bcc) species. In the CF lung, these bacteria grow as multicellular aggregates termed biofilms. Biofilms demonstrate increased (adaptive) resistance to conventional antibiotics, and there are currently no available biofilm-specific therapies. Using plastic adherent, hydroxyapatite and flow cell biofilm models coupled with confocal and scanning electron microscopy, it was demonstrated that an anti-biofilm peptide 1018 prevented biofilm formation, eradicated mature biofilms and killed biofilms formed by a wide range of P. aeruginosa and B. cenocepacia clinical isolates. New peptide derivatives were designed that, compared to their parent peptide 1018, showed similar or decreased anti-biofilm activity against P. aeruginosa biofilms, but increased activity against biofilms formed by the Gram-positive bacterium methicillin resistant Staphylococcus aureus. In addition, some of these new peptide derivatives retained the immunomodulatory activity of 1018 since they induced the production of the chemokine monocyte chemotactic protein-1 (MCP-1) and suppressed lipopolysaccharide-mediated tumor necrosis factor-α (TNF-α) production by human peripheral blood mononuclear cells (PBMC) and were non-toxic towards these cells. Peptide 1018 and its derivatives provide promising leads for the treatment of chronic biofilm infections and hyperinflammatory lung disease in CF patients.


  • Open Access

    Fosmidomycin Decreases Membrane Hopanoids and Potentiates the Effects of Colistin on Burkholderia multivorans Clinical Isolates

    by Rebecca J. Malott, Chia-Hung Wu, Tracy D. Lee, Trevor J. Hird, Nathan F. Dalleska, James E. A. Zlosnik, Dianne K. Newman, David P. Speert

    Burkholderia cepacia complex (Bcc) pulmonary infections in people living with cystic fibrosis (CF) are difficult to treat because of the extreme intrinsic resistance of most isolates to a broad range of antimicrobials. Fosmidomycin is an antibacterial and antiparasitic agent that disrupts the isoprenoid biosynthesis pathway, a precursor to hopanoid biosynthesis. Hopanoids are involved in membrane stability and contribute to polymyxin resistance in Bcc bacteria. Checkerboard MIC assays determined that although isolates of the Bcc species B. multivorans were highly resistant to treatment with fosmidomycin or colistin (polymyxin E), antimicrobial synergy was observed in certain isolates when the antimicrobials were used in combination. Treatment with fosmidomycin decreased the MIC of colistin for isolates as much as 64-fold to as low as 8 μg/ml, a concentration achievable with colistin inhalation therapy. A liquid chromatography-tandem mass spectrometry technique was developed for the accurate quantitative determination of underivatized hopanoids in total lipid extracts, and bacteriohopanetetrol cyclitol ether (BHT-CE) was found to be the dominant hopanoid made by B. multivorans . The amount of BHT-CE made was significantly reduced upon fosmidomycin treatment of the bacteria. Uptake assays with 1- N -phenylnaphthylamine were used to determine that dual treatment with fosmidomycin and colistin increases membrane permeability, while binding assays with boron-dipyrromethene-conjugated polymyxin B illustrated that the addition of fosmidomycin had no impact on polymyxin binding. This work indicates that pharmacological suppression of membrane hopanoids with fosmidomycin treatment can increase the susceptibility of certain clinical B. multivorans isolates to colistin, an agent currently in use to treat pulmonary infections in CF patients.


  • Open Access

    Investigation of aminoglycoside resistance inducing conditions and a putative AmrAB-OprM efflux system in Burkholderia vietnamiensis

    by Agatha N Jassem, Connor M Forbes, David P Speert

    Burkholderia cepacia complex (BCC) bacteria are highly virulent, typically multidrug-resistant, opportunistic pathogens in cystic fibrosis (CF) patients and other immunocompromised individuals. B. vietnamiensis is more often susceptible to aminoglycosides than other BCC species, and strains acquire aminoglycoside resistance during chronic CF infection and under tobramycin and azithromycin exposure in vitro, apparently from gain of antimicrobial efflux as determined through pump inhibition. The aims of the present study were to determine if oxidative stress could also induce aminoglycoside resistance and provide further observations in support of a role for antimicrobial efflux in aminoglycoside resistance in B. vietnamiensis.


  • Comparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosis

    by V. Waters, J. E. A. Zlosnik, Y. C. W. Yau, D. P. Speert, S. D. Aaron, D. S. Guttman

    The aim of this study was to compare two traditional pattern matching techniques, pulsed-field gel electrophoresis (PFGE) and random amplified polymorphic DNA (RAPD), with the more reproducible technique of multilocus sequence typing (MLST) to genotype a blinded sample of Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients. A blinded sample of 48 well-characterized CF P. aeruginosa isolates was genotyped by PFGE, RAPD, and MLST, each performed in a different laboratory. The discriminatory power and congruence between the methods were compared using the Simpson’s index, Rand index, and Wallace coefficient. PFGE and MLST had the greatest congruence with the highest Rand index (0.697). The discriminatory power of PFGE, RAPD, and MLST were comparable, with high Simpson’s indices (range 0.973–0.980). MLST identified the most clonal relationships. When clonality was defined as agreement between two or more methods, MLST had the greatest predictive value (100 %) in labeling strains as unique, while PFGE had the greatest predictive value (96 %) in labeling strains as clonal. This study demonstrated the highest level of agreement between PFGE and MLST in genotyping P. aeruginosa isolates from CF patients. MLST had the greatest predictive value in identifying strains as unique and, thus, has the potential to be a cost-efficient, high-throughput, first-pass typing method.


  • Open Access

    Serum Susceptibility in Clinical Isolates of Burkholderia Cepacia Complex Bacteria: Development of a Growth-Based Assay for High Throughput Determination

    by James E. A. Zlosnik, L. Cynthia Gunaratnam, David P. Speert

    Burkholderia cepacia complex (BCC) bacteria can cause devastating chronic infections in people with cystic fibrosis (CF). Of particular concern is ‘cepacia syndrome’, a rapidly progressive and usually fatal decline in health, characterised by a necrotizing bacteremic pneumonia. An important component of defence against blood stream infections is the bactericidal action of serum. Traditional methods to determine the capacity of bacterial isolates to resist the bactericidal effects of serum are relatively low throughput, viability assays. In this study, we developed a novel growth-based assay for serum susceptibility, which allows for high throughput analysis. We applied this assay to a range of clinical isolates of BCC and found no direct link between the mucoid phenotype and susceptibility to the inhibitory effects of serum. Of particular clinical significance, we also found no direct link between the last isolate from patients who subsequently developed ‘cepacia syndrome’ and its capacity to resist the inhibitory effects of human serum, indicating serum resistance cannot be used as a marker of an isolate’s capacity to escape from the lung and cause bacteremia.


  • Pseudomonas

    by Deborah A. Henry, David P. Speert

    As polyphasic taxonomy continues to advance, more changes will doubtlessly arise; a clinical laboratory must keep abreast of such changes, in order to differentiate these isolates from the more clinically important Pseudomonas species. Healthy individuals are resistant to serious infections by all Pseudomonas species, including P. aeruginosa. Immunocompromised hosts are occasionally infected with one of the many non-aeruginosa species, including (but not limited to) P. fluorescens, P. putida, P. stutzeri, P. oryzihabitans, P. luteola, P. alcaligenes, P. mendocina, and P. veronii. Historically, typing of P. aeruginosa for epidemiological purposes has relied upon phenotypic characteristics of the bacteria. The most widely used method was based upon differences in LPS O polysaccharide (LPS serotyping). Several genotypic methods have been developed over the past two decades for typing P. aeruginosa for epidemiological purposes. Isolates from sites of chronic infection, such as cystic fibrosis (CF) respiratory sites, often exhibit multiple morphotypes that can make identification difficult. Molecular methods increasingly are finding a role in the identification of this organism, especially for epidemiological studies. Susceptibility testing of P. aeruginosa is difficult, especially for mucoid isolates, due to increasing resistance, lack of reproducibility of results, and lack of clinical correlation. A basic understanding of the multiple mechanisms of resistance, both intrinsic and acquired, is essential to interpret susceptibility testing results and give therapeutic recommendations to physicians. Other Pseudomonas species are infrequently isolated in the laboratory and are usually not clinically significant. Clinical correlation and correlation with the Gram stain are essential before further workup is undertaken.


  • Open Access

    In Vitro Susceptibility of Burkholderia vietnamiensis to Aminoglycosides

    by Agatha N. Jassem, James E. A. Zlosnik, Deborah A. Henry, Robert E. W. Hancock, Robert K. Ernst, David P. Speert

    Burkholderia cepacia complex (BCC) bacteria are opportunistic pathogens that can cause severe disease in cystic fibrosis (CF) patients and other immunocompromised individuals and are typically multidrug resistant. Here we observed that unlike other BCC species, most environmental and clinical Burkholderia vietnamiensis isolates were intrinsically susceptible to aminoglycosides but not to cationic antimicrobial peptides or polymyxin B. Furthermore, strains acquired aminoglycoside resistance during chronic CF infection, a phenomenon that could be induced under tobramycin or azithromycin pressure in vitro . In comparing susceptible and resistant B. vietnamiensis isolates, no gross differences in lipopolysaccharide structure were observed, all had lipid A-associated 4-amino-4- deoxy - l -arabinose residues, and all were resistant to the permeabilizing effects of aminoglycosides, a measure of drug entry via self-promoted uptake. However, susceptible isolates accumulated 5 to 6 times more gentamicin than a resistant isolate, and aminoglycoside susceptibility increased in the presence of an efflux pump inhibitor. B. vietnamiensis is therefore unusual among BCC bacteria in its susceptibility to aminoglycosides and capacity to acquire resistance. Aminoglycoside resistance appears to be due to decreased cellular accumulation as a result of active efflux.